BioCryst shareholders approve 11M share increase in stock incentive plan at annual meeting

BIOCRYST PHARMACEUTICALS INC

Director George Abercrombie retired effective June 12, 2025 after 13 years; no disagreement cited.
Shareholders approved amended Stock Incentive Plan, increasing shares available by 11,000,000 to 81,090,000 total.
Advisory say-on-pay passed with 143.1M for vs 6.4M against; auditor Ernst & Young ratified with 174.7M for.
Director nominees Steven Galson and Alan Levin re-elected with ~146M votes each.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

George B. Abercrombie

Director

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2025-06-12
Filed: June 16, 2025, 7:59 PM ET

On June 11, 2025, George B. Abercrombie notified BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), of his intention to retire from the Board of Directors of the Company (the “Board”), effective as of the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

George B. Abercrombie retired as Director at BIOCRYST PHARMACEUTICALS INC.

Action: retired
Role: Director

Exact text from the filing

On June 11, 2025, George B. Abercrombie notified BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), of his intention to retire from the Board of Directors of the Company (the “Board”), effective as of the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).

View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-25-003910

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.